Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
25 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
RuiYi Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'RuiYi Inc. - Product Pipeline Review - 2015', provides an overview of the RuiYi Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of RuiYi Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of RuiYi Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of RuiYi Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the RuiYi Inc.'s pipeline products Reasons to Buy - Evaluate RuiYi Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of RuiYi Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the RuiYi Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of RuiYi Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of RuiYi Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of RuiYi Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 RuiYi Inc. Snapshot 5 RuiYi Inc. Overview 5 Key Information 5 Key Facts 5 RuiYi Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 RuiYi Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 RuiYi Inc. - Pipeline Products Glance 10 RuiYi Inc. - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 RuiYi Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 RuiYi Inc. - Drug Profiles 13 RYI-008 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 RYI-018 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 RYI-028 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Monoclonal Antibodies for Multiple Sclerosis 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Monoclonal Antibodies for Undisclosed Indication 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 RuiYi Inc. - Pipeline Analysis 18 RuiYi Inc. - Pipeline Products by Target 18 RuiYi Inc. - Pipeline Products by Molecule Type 19 RuiYi Inc. - Pipeline Products by Mechanism of Action 20 RuiYi Inc. - Recent Pipeline Updates 21 RuiYi Inc. - Dormant Projects 22 RuiYi Inc. - Locations And Subsidiaries 23 Head Office 23 Other Locations & Subsidiaries 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 24 Disclaimer 25
List of Tables
RuiYi Inc., Key Information 5 RuiYi Inc., Key Facts 5 RuiYi Inc. - Pipeline by Indication, 2015 7 RuiYi Inc. - Pipeline by Stage of Development, 2015 8 RuiYi Inc. - Monotherapy Products in Pipeline, 2015 9 RuiYi Inc. - Phase I, 2015 10 RuiYi Inc. - Preclinical, 2015 11 RuiYi Inc. - Discovery, 2015 12 RuiYi Inc. - Pipeline by Target, 2015 18 RuiYi Inc. - Pipeline by Molecule Type, 2015 19 RuiYi Inc. - Pipeline Products by Mechanism of Action, 2015 20 RuiYi Inc. - Recent Pipeline Updates, 2015 21 RuiYi Inc. - Dormant Developmental Projects,2015 22 RuiYi Inc., Other Locations 23
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.